Skip to main content
HRMY
NASDAQ Life Sciences

Former CFO Sandip Kapadia Files Intent to Sell $1.6M in Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$35.47
Mkt Cap
$2.053B
52W Low
$25.52
52W High
$40.87
52W Position info
39% above low
Off High info
13% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

HRMY sits 39% above its 52-week low of $25.52 on elevated volume (2.1× avg).

Summary

Former CFO Sandip Kapadia filed a Form 144 to sell $1.6 million worth of Harmony Biosciences stock, continuing a trend of share dispositions by the former executive.


Key Events · Ownership and Investor Activity · HRMY

  • Intent to Sell Shares

    Former CFO Sandip Kapadia filed a Form 144 to sell 45,594 shares of common stock, valued at approximately $1.6 million.

  • Acquisition via Option Exercise

    The shares intended for sale were acquired through the exercise of options under a registered plan.

  • Ongoing Executive Sales

    This filing is part of a pattern, as Kapadia has sold an additional 87,012 shares totaling over $2.8 million in gross proceeds over the past three months.


Analysis · HRMY · Life Sciences

Former CFO Sandip Kapadia has filed a Form 144 indicating his intent to sell 45,594 shares of Harmony Biosciences stock, valued at approximately $1.6 million. This proposed sale follows a pattern of dispositions by Kapadia, who has sold over $2.8 million in shares in the past three months. The shares to be sold were acquired through the exercise of options. This ongoing selling activity by a former executive could be interpreted as a move for personal liquidity or a lack of confidence.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HRMY was trading at $35.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $25.52 to $40.87. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HRMY - Latest Insights

HRMY
Nov 04, 2026, 8:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $35.94
Real-time Price: $33.00 info
Change: -$2.94 (-8%) info
Market Cap: $1.939B info
HRMY
Nov 04, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.18
Real-time Price: $33.00 info
Change: -$3.18 (-9%) info
Market Cap: $1.939B info
HRMY
Nov 04, 2026, 7:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $36.50
Real-time Price: $33.00 info
Change: -$3.50 (-10%) info
Market Cap: $1.939B info
HRMY
Oct 22, 2026, 3:57 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $36.03
Real-time Price: $33.00 info
Change: -$3.03 (-8%) info
Market Cap: $1.939B info
HRMY
Oct 13, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.40
Real-time Price: $33.00 info
Change: -$5.40 (-14%) info
Market Cap: $1.939B info